Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
Maxwell Skor

Maxwell Skor Analyst Performance

Vice President, Biotech Equity Research at Morgan Stanley

Maxwell Skor is a stock analyst at Morgan Stanley in the medical sector, covering 8 publicly traded companies. Over the past year, Maxwell Skor has issued 11 stock ratings, including buy, hold, and sell recommendations. While full access to Maxwell Skor's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Maxwell Skor's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 1 Years
Buy Recommendations
63.64% 7 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy63.6%7 ratings
Hold27.3%3 ratings
Sell9.1%1 ratings

Out of 11 total stock ratings issued by Maxwell Skor at Morgan Stanley, the majority (63.6%) have been Buy recommendations, followed by 27.3% Hold and 9.1% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
8 companies

Maxwell Skor, an analyst at Morgan Stanley, currently covers 8 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Maxwell Skor of Morgan Stanley specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
8 companies
100.0%

Maxwell Skor's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
3/17/2026Reiterated Rating$5.24$13.00Sell
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
3/13/2026Reiterated Rating$3.29$12.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/12/2026Reiterated Rating$221.49$256.00Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1/9/2026Initiated Coverage$63.40$115.00Overweight
Insmed, Inc. stock logo
INSM
Insmed
1/8/2026Set Price Target$172.80$157.00
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
1/8/2026Set Price Target$64.81$90.00
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
11/17/2025Downgrade$217.78Equal Weight
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
10/16/2025Initiated Coverage$105.62$190.00Overweight
Insmed, Inc. stock logo
INSM
Insmed
8/21/2025Boost Price Target$129.45$144.00Equal Weight
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
7/3/2025Initiated Coverage$2.92$12.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
7/3/2025Initiated Coverage$173.10$250.00Overweight
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
5/5/2025Set Price Target$9.06$17.00Equal Weight
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3/14/2025Reiterated Rating$1.81$10.00Overweight